Skip to content

OZEMRoundhill Glp-1 & Weight Loss ETF

Grow my money2y track recordRanked #1,794 of 2,992 in this goal

Seeks capital appreciation.

By Roundhill Investments · Launched 2024

Annual Cost

0.59%

#3,116 of 5,854 · average

Fund Size

$54M

#3,574 of 5,854 · mid-size

Return (1Y)Goal

+29.3%

Track Record

2 years

#3,488 of 5,854 · seasoned

Performance

Total-return NAV · USD
Growth of $10,000
$13,319+33.2%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Cap

Multi cap

Strategy

Active selection

Focus

Obesity & GLP-1

What it actually holds

By weight

Concentration

Top 10 holdings = 75.6% of fundconcentrated

Eli Lilly & Co
16.1%
Novo Nordisk A/S
13.1%
Mount Vernon Liquid Assets Portfolio, LLC
12.1%
Pfizer Inc
7.6%
Viking Therapeutics Inc
5.3%
Innovent Biologics Inc
5.1%
Ascletis Pharma Inc
4.7%
Amgen Inc
3.9%
Roche Holding AG
3.9%
AstraZeneca PLC
3.8%

Asset allocation

Stocks
99.6%
Other
2.6%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
23.6%High

Year-on-year price swings

Max drawdown
-28.6%Moderate

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks capital appreciation.
Strategy
Actively manages a portfolio focused on equity securities of GLP-1 & Weight Loss Companies, prioritizing those involved in developing drugs for weight loss. Concentrates investments in the health care sector, including small-, mid-, and large-cap companies in both U.S. and non-U.S. markets.
Inception date
May 20, 2024
Fund family
Roundhill Investments

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

These usually launch after the gains are gone

A theme gets packaged into a fund after it has already run. Over the past 15 years, fewer than one in 10 thematic funds beat a broad global index, and more than three-quarters closed down entirely. The pitch always sounds good. The returns rarely follow.

Sources: Morningstar, 'Global Thematic Funds Landscape' (2022)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at OZEM. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

Data updated on 2026-08-04